STAAR Surgical Faces Revenue Declines and Cash Burn, StockStory Says Avoid

StockStory·3 Jul 2026·Read original

2▲0 ▼1Impact / 5

Analyst Health Care Equipment & Supplies

Summary · why it matters

StockStory analysts recommend avoiding STAAR Surgical despite its recent 16.2% gain to $27.81, citing three concerns. The company's revenue has declined at an annualized rate of 5.7% over the past two years, its free cash flow margin has dropped by 26.6 percentage points over five years to negative 18.9%, and its return on invested capital has significantly decreased, signaling limited profitable growth opportunities. With the stock trading at 37 times forward earnings, the analysts believe better opportunities exist elsewhere.

STAAR Surgical Company ▼